Recursion Pharmaceuticals, Inc. (RXRX) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Recursion Pharmaceuticals (RXRX) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. The thesis is that Recursion runs one of the largest industrial-scale AI drug-discovery platforms, pairing high-throughput biological imaging with automated molecular design (sharpened by the 2024 Exscientia merger) and a wholly owned NVIDIA-built supercomputer, and that this data and compute advantage can produce drugs faster and cheaper than traditional pharma. The single biggest risk is that none of this has yet been proven by an approved medicine: Recursion is pre-profit, losing about $131 million in Q2 2026 against roughly $7.7 million of revenue, and the entire value rests on clinical programs that could still fail in trials. In October 2026 it raised $200 million in new stock at $3.25 a share alongside encouraging REC-4881 data and a Sanofi option, extending its stated cash runway into 2029; the shares closed near $3.69 on October 16, 2026, down about 12% year to date.

RXRX stock price

As of 2026-11-16, Recursion Pharmaceuticals, Inc. (RXRX) last closed at $2.90, down 29.5% over the past year. Over the past 52 weeks it has traded between $2.84 and $4.96.

RXRX last close
$2.90
1 day
-8.79%
1 month
-16.16%
1 year
-29.49%
52-week range
$2.84 to $4.96
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Recursion Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.

RXRX key stats

At $2.91 on November 16, 2026, Recursion Pharmaceuticals, Inc. (RXRX) has a market cap of $1.8B.

Market cap
$1.8B
Price to book
1.8
Beta
1.15

Market cap, P/E and yield are measured at the $2.91 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Recursion Pharmaceuticals, Inc. (RXRX)?

The last two weeks for Recursion Pharmaceuticals, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • RXRX closed at $2.90 on November 16, 2026, down 23.7% over the past five trading days (from $3.81).

Recursion Pharmaceuticals, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Recursion Pharmaceuticals, Inc. (RXRX) latest quarter

Recursion reported revenue of $18.6 million for Q3 2026, up 258% from a year earlier (Recursion, Nov 2, 2026).

Revenue
$18.6 million
up 258% from a year earlier
Diluted EPS
-$0.22
n/a
Operating revenue
$18.1 million
up 262% from a year earlier

Source: Recursion Q3 2026 results, Nov 2, 2026. Full earnings breakdown

What does Recursion Pharmaceuticals, Inc. (RXRX) do?

Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery. Its platform combines automated wet-lab biology, high-throughput cellular imaging that generates petabytes of proprietary experimental data, and machine-learning models that map relationships between genes, compounds, and disease, layered with Exscientia's automated precision molecular design. Recursion intends to make money three ways: partnership and collaboration payments (upfront fees, research funding, and milestone payments from large pharma companies that use its platform), future royalties on any partnered drugs that reach market, and value from its own wholly owned pipeline of clinical candidates. Today the company is pre-revenue in the product sense: reported revenue is small (roughly $6.5 million in Q1 2026 and $7.7 million in Q2 2026) and comes mostly from partnerships rather than drug sales.

Recursion went public in 2021 and has built its profile around scale and compute. It owns BioHive, an NVIDIA-built supercomputer (BioHive-2 is powered by dozens of NVIDIA DGX H100 systems and hundreds of H100 GPUs), and NVIDIA has been both a technology partner and an investor, which fueled the market's framing of Recursion as an AI-biotech bellwether. In 2024 Recursion agreed to merge with UK-based Exscientia in a roughly $700 million all-stock deal that closed and combined two AI drug-discovery leaders, bringing together partnerships with Roche-Genentech and Bayer (Recursion) and Sanofi and Merck KGaA (Exscientia). Since the merger the company has reworked and prioritized its pipeline, cut operating expenses, and emphasized extending its cash runway while advancing a handful of Phase 2 clinical programs.

The October 15, 2026 update was the biggest news of the year. Recursion sold about 61.5 million shares at $3.25 each, a 13% discount to the prior close, for about $200 million of gross proceeds from investors including Janus Henderson, Invus, ARK Invest and Driehaus, and said its preliminary September 30 cash of about $561 million plus the proceeds funds operations into 2029. The same day it reported Phase 1b/2 TUPELO data for REC-4881 in familial adenomatous polyposis (87% of patients had less total polyp burden after 12 weeks, with a 47% median reduction) and targeted a registrational trial start in the second half of 2027, reported three partial responses for the RBM39 degrader REC-1245 in endometrial and liver cancer, and said Sanofi had optioned a first-in-class oral immunology candidate, triggering a $10 million milestone. The shares rose more than 16% during trading on October 15, their best day in nearly a year, and closed near $3.69 on October 16, 2026, down about 12% year to date and about 42% over the past year. In the second quarter of 2026 Recursion reported revenue of about $7.7 million and a net loss of about $131 million, with a loss per share of $0.25 against a $0.23 estimate; third-quarter results are expected around November 4, 2026.

What's driving Recursion Pharmaceuticals, Inc. (RXRX)?

An industrial-scale AI platform and proprietary data moat

Recursion's core argument is that drug discovery becomes a data and compute problem at scale. It has run vast numbers of automated biological experiments to build one of the largest proprietary maps of cellular biology, the kind of dataset that is expensive and slow for others to reproduce. The bet is that this data advantage, fed into machine-learning models, can surface drug targets and candidates faster and at lower cost than conventional trial-and-error chemistry.

A deep big-pharma partnership book

Recursion has signed collaborations with major drug makers including Roche-Genentech, Bayer, Sanofi, and Merck KGaA. Management has pointed to more than $20 billion in potential future milestone payments across these deals, before any royalties on net sales. These partnerships validate the platform externally, fund operations with non-dilutive cash, and give Recursion multiple shots on goal without bearing all the clinical cost itself. In October 2026 Sanofi optioned the first development candidate from its collaboration, an oral first-in-class immunology molecule, paying Recursion a $10 million milestone and taking total upfront and milestone payments under that deal to $144 million, with more than $300 million of further milestones possible plus low double-digit royalties.

The NVIDIA tie and owned supercomputing

Recursion owns BioHive, an NVIDIA-built supercomputer that the company has described as among the most powerful AI systems wholly owned by any biopharma. NVIDIA has been a technology collaborator and investor, reinforcing the narrative that Recursion sits at the intersection of AI infrastructure and biology. Owning its compute lets Recursion train large biological models on its own data without renting capacity from cloud providers.

A broadened, post-merger pipeline

The Exscientia merger combined Recursion's biology-first platform with Exscientia's molecular design and added clinical assets and partnerships. The company now focuses on REC-4881 in familial adenomatous polyposis (FDA Fast Track and Orphan Drug designations), the RBM39 degrader REC-1245 in solid tumors, REC-4539 (LSD1), REC-7735 (PI3K alpha H1047R) and REC-102 (ENPP1, hypophosphatasia), and plans to seek partners for REC-617 (CDK7) and REC-3565 (MALT1). October 2026 data showed a 47% median reduction in total polyp burden at 12 weeks for REC-4881, with a registrational trial targeted for the second half of 2027, and REC-1245 produced three partial responses with 45 mg chosen for expansion. Pipeline breadth gives the platform several independent chances to produce a clinical win that would re-rate the whole thesis.

What are the risks to Recursion Pharmaceuticals, Inc. (RXRX)?

The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $131 million in Q2 2026 against only about $7.7 million of revenue, and about $519 million over the trailing twelve months, so the entire valuation rests on platform promise rather than proven output. AI-driven drug discovery as a category is still unproven at the finish line, and skeptics note that no AI-originated compound has yet delivered a blockbuster approval, leaving open the possibility that the platform advantage does not translate into clinical success. Early data such as the REC-4881 and REC-1245 results come from small, open-label studies, and Recursion's candidates could still fail in larger trials like most clinical-stage biotech assets do; even partnered programs depend on decisions outside Recursion's control. Dilution is not hypothetical: the October 2026 offering added about 61.5 million shares at $3.25, and although the company now guides to a cash runway into 2029, continued losses mean it may need to raise capital again. The stock has also been volatile, down about 42% over the past year and trading well below its 52-week high of about $7.18.

What is the Recursion Pharmaceuticals, Inc. (RXRX) forecast?

6 analysts publish price targets on RXRX, averaging $7.32 as of November 2026, or +151.5% against the $2.91 share price on November 16, 2026. The published targets run from $4.00 to $10.00, a wide spread, and the ratings split 3 buy, 4 hold, 0 sell. Over the last six months there have been 0 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full RXRX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is RXRX a buy or a sell?

We give no verdict on Recursion Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. An industrial-scale AI platform and proprietary data moat. Recursion's core argument is that drug discovery becomes a data and compute problem at scale. The most optimistic published target, $10.00, assumes this works close to its best case.

The case against. The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $131 million in Q2 2026 against only about $7.7 million of revenue, and about $519 million over the trailing twelve months, so the entire valuation rests on platform promise rather than proven output. The most pessimistic target, $4.00, is roughly what RXRX is worth if this bites instead.

Read the full bull and bear case on RXRX, including what would have to change to break either one. Walnut is not an investment adviser.

Has Recursion Pharmaceuticals, Inc. (RXRX) split its stock?

No. Recursion Pharmaceuticals, Inc. (RXRX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Recursion Pharmaceuticals, Inc. (RXRX) valued?

Market cap, P/E and dividend yield at today's price are in the RXRX key stats above. The business figures below come from Recursion Pharmaceuticals, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (Q2 2026): ~$7.7 million (TTM ~$55 million, mostly partnership and milestone revenue)
  • Net loss (Q2 2026): ~$131 million (TTM ~$519 million); EPS -$0.25 vs -$0.23 expected
  • Cash: ~$561 million on September 30, 2026 (preliminary), before ~$200 million of offering proceeds
  • Stated cash runway: Into 2029, including net proceeds of the October 2026 offering
  • October 2026 offering: ~61.5 million shares at $3.25 (~$200 million gross)

As of October 2026: Because Recursion is pre-profit with minimal revenue, traditional earnings multiples do not apply, and the figures that matter most are cash on hand, the rate of cash burn, and how long the runway lasts before the company must raise money again. The October 2026 offering pushed the stated runway into 2029 at the cost of about 61.5 million new shares, while REC-4881 data and the Sanofi option added evidence on the pipeline side. Valuation is still a bet on future platform output and partnership milestones rather than on current financial performance, and Q3 2026 results are expected around November 4.

Which ETFs hold Recursion Pharmaceuticals, Inc. (RXRX)?

If you want RXRX exposure as part of a larger bundle, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

ETFName% in RXRXExpense ratio
ROBTFirst Trust Nasdaq Artificial Intelligence and Robotics ETF1.89%0.65%

Who competes with Recursion Pharmaceuticals, Inc. (RXRX)?

Other AI-native drug-discovery companies

Publicly traded peers building platforms that use machine learning to find or design drugs include Schrodinger (physics-based molecular modeling pivoting toward its own pipeline), Absci (generative AI for de novo antibody design), Relay Therapeutics (protein-motion-based discovery), and Insilico Medicine. These are the closest comparables to Recursion's thesis and compete for talent, partnerships, and investor attention in the AI-biotech category.

Traditional clinical-stage biotech

Recursion's wholly owned programs compete on conventional clinical merit against the broad universe of small and mid-cap biotech companies targeting the same diseases, such as rare oncology and neurology indications. In that arena the AI origin story matters less than trial data: a program succeeds or fails on safety and efficacy like any other, regardless of how the candidate was discovered.

Big pharma in-house AI and platform spend

Large pharmaceutical companies are also building or buying their own AI and computational-discovery capabilities, and several are simultaneously Recursion's partners and potential competitors. Their scale, capital, and proprietary data mean Recursion must keep demonstrating that an independent, full-stack platform offers something the incumbents cannot easily replicate internally.

What stocks are similar to Recursion Pharmaceuticals, Inc. (RXRX)?

Other names that sit close to RXRX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Recursion Pharmaceuticals, Inc. (RXRX)

There are three common ways to get RXRX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (ROBT), which spreads the position across many companies. Or build it into a focused thematic portfolio, so RXRX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where RXRX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Recursion Pharmaceuticals, Inc. (RXRX)

Recursion right now is a clinical-stage, platform-first AI biotech, not a product company: its main driver is a discovery engine plus a deep partnership book (Roche-Genentech, Bayer, Sanofi, Merck KGaA and others, with management citing more than $20 billion in potential future milestones), and the metric that matters most is cash, about $561 million on September 30, 2026 (preliminary) before a $200 million October offering that management says funds operations into 2029. If you believe that scaled AI plus proprietary biological data will eventually translate into approved drugs and royalty streams, the question becomes sizing and overlap with the rest of a portfolio, not timing; the risk is that the platform stays a promise, the wholly owned pipeline (REC-4881, REC-1245 and others) disappoints in later trials, and continued losses force further dilutive financing before any drug reaches the market.

More on Recursion Pharmaceuticals, Inc. (RXRX)

Whether RXRX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RXRX a buy or a sell?, and where the stock could go from here in the RXRX stock forecast.

For income investors, whether RXRX pays a dividend and how the payout looks is covered in does RXRX pay a dividend? And to weigh RXRX against a peer, read the full side-by-side comparisons: RXRX vs TEM and RXRX vs ILMN.

Wondering how RXRX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Recursion Pharmaceuticals, Inc.

Ask Walnut's AI anything about RXRX and see how it fits what you own.

FAQ

Is RXRX a good stock to buy right now?

+

That depends entirely on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a scaled AI platform, deep pharma partnerships, encouraging October 2026 REC-4881 data, and a cash runway into 2029. The bear case is that Recursion has no approved drug, loses over $100 million a quarter, and could fail in trials or need more dilutive financing after the October 2026 offering. It is a speculative, high-volatility holding, not a stable one.

What does Recursion Pharmaceuticals do?

+

Recursion is a clinical-stage biotech that aims to industrialize drug discovery using artificial intelligence. It runs automated biology experiments at massive scale, captures the results as proprietary imaging data, and uses machine-learning models, plus Exscientia's molecular design tools, to identify and design drug candidates. It earns money mainly through partnerships with large pharma companies and is advancing its own pipeline of experimental medicines.

Is RXRX profitable?

+

No. Recursion is not profitable and remains deeply loss-making, reporting a net loss of roughly $131 million in the second quarter of 2026 against only about $7.7 million of revenue, and about $519 million over the trailing twelve months. Like most clinical-stage biotech companies, it spends heavily on research and trials years before any product could generate meaningful sales, so profitability is not expected in the near term.

Does RXRX pay a dividend?

+

No. Recursion does not pay a dividend and is not expected to. As an unprofitable, cash-burning clinical-stage company, it directs all available capital toward research, clinical trials, and its computing platform rather than returning cash to shareholders. Investors in a stock like this are betting on potential future share-price appreciation, not income.

Is Recursion a real AI drug company?

+

Yes, Recursion genuinely uses AI and large-scale automated biology as the core of its discovery process, and it owns an NVIDIA-built supercomputer to train its models. What remains unproven is the payoff: no AI-discovered drug, from Recursion or its peers, has yet reached a major approval. So it is a real AI company whose central claim, that AI produces better drugs faster, has not been validated in the market.

What happened with the Recursion and Exscientia merger?

+

In 2024 Recursion agreed to merge with UK-based Exscientia in an all-stock deal valued at roughly $700 million, combining two leading AI drug-discovery platforms. The deal brought together Recursion's biology-first imaging approach with Exscientia's automated molecular design, plus partnerships including Roche-Genentech, Bayer, Sanofi, and Merck KGaA. Since closing, Recursion has reworked its pipeline and cut costs to extend its cash runway, and in October 2026 Sanofi optioned the first candidate from the collaboration Exscientia originally signed.

How is Recursion connected to NVIDIA?

+

NVIDIA has been both a technology partner and an investor in Recursion. Recursion owns BioHive, a supercomputer built with NVIDIA hardware (BioHive-2 uses dozens of NVIDIA DGX H100 systems and hundreds of H100 GPUs), which it uses to train large biological models on its proprietary data. That relationship is a big reason the market often frames Recursion as a bellwether for AI in biotech.

Can I hold RXRX in a thematic basket or through an ETF?

+

Yes. RXRX trades on the Nasdaq, so you can buy shares or fractional shares at any major broker and hold it as one position within a thematic basket, for example an AI-in-healthcare or innovative-biotech theme. It is also included in some growth, biotech, and genomics or innovation ETFs, which give diversified exposure so a single clinical setback affects less of your overall holding.

Why did Recursion raise $200 million in October 2026?

+

On October 15, 2026 Recursion priced an oversubscribed offering of about 61.5 million shares at $3.25, a 13% discount to the prior close, for about $200 million of gross proceeds. Buyers included Janus Henderson, Invus, ARK Invest and Driehaus. Combined with preliminary cash of about $561 million at September 30, the company says the proceeds fund operations into 2029, past the planned 2027 start of a registrational REC-4881 trial.

What did the REC-4881 data show?

+

In the Phase 1b/2 TUPELO study in familial adenomatous polyposis, reported October 15, 2026, 87% of patients had a reduction in total polyp burden after 12 weeks at 4 mg daily, with a 47% median reduction, and 85% remained below baseline 12 weeks after stopping treatment. There were no Grade 4 or higher treatment-related events, though four patients discontinued for adverse events. Recursion is targeting a registrational trial start in the second half of 2027, pending FDA discussions.

How has RXRX stock performed in 2026?

+

As of October 16, 2026 RXRX closed near $3.69, down about 12% year to date and about 42% over the past year, within a 52-week range of about $2.77 to $7.18. It is up about 20% over three months and jumped more than 16% during trading on October 15 on the offering, data and Sanofi news. The six analysts covering it have a mean target of about $7.32. Walnut is not an investment adviser, and this is not a recommendation.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Recursion Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.